Titan Pharmaceuticals, Inc.

281 articles about Titan Pharmaceuticals, Inc.

• Titan Pharmaceuticals Enters Into Definitive Agreement To Acquire JT Pharma's Kappa Opioid Agonist Peptide, JT-09

  10/28/2020

  - Titan today announced that it has entered into a definitive asset purchase agreement (the "Agreement") with JT Pharmaceuticals, Inc.

• Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

  10/28/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $0.10 per unit.  Each unit issued in the offering consists of one share of common stock and one warrant to purchase one share of common stock.  Gross proceeds, before underwritin

• Titan Pharmaceuticals Announces Debt Settlement Agreement with Molteni and Horizon

  10/26/2020

  Titan Pharmaceuticals, Inc. announced its entry into an agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio S.p.A and Horizon Credit LLC II.

• Titan Pharmaceuticals Provides a Strategic & Corporate Update

  10/15/2020

  Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ("Titan" or the "Company") today announced a strategic restructuring designed to position it for future growth. Specifically, the Company plans to:

• Titan Pharmaceuticals Announces Pricing of $2.7 Million Registered Direct Offering

  9/24/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a share purchase agreement with certain accredited institutional investors to purchase 19,440,000 shares of its common stock in a registered direct offering at a purchase price of $0.14 per share.

• Titan Pharmaceuticals' Stockholders Approve Proposal To Amend Its Certificate Of Incorporation

  9/18/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, at today's special meeting, its stockholders approved the proposal to amend Titan's certificate of incorporation to increase the number of authorized shares of common stock from 125 million to 225 million (the "Amendment")

• Titan's Probuphine® Commercialization Partner, Molteni, Enters Into Exclusive European Distribution Agreement With Accord Healthcare

  9/15/2020

  Titan Pharmaceuticals, Inc. announced that its partner, Molteni Farmaceutici, has entered into an exclusive distribution agreement with Accord Healthcare Europe for the commercialization of Sixmo®-, the brand name for Probuphine® in the European Union.

• Titan Pharmaceuticals Provides Update To Stockholders On Proposal To Amend Its Certificate Of Incorporation

  9/14/2020

   Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today provided an update on the upcoming special meeting of stockholders (the "Meeting") in response to recent stockholder inquiries regarding the number of meeting adjournments. The sole purpose of the Meeting is to seek approval of a proposal to

• Titan Pharmaceuticals Reports Second Quarter 2020 Financial Results

  8/14/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the second quarter ended June 30, 2020 and provided an update on its business.

• Titan Pharmaceuticals Urges Stockholders to Vote "FOR" Proposal to Amend Its Certificate of Incorporation

  7/8/2020

  - A special meeting of stockholders (the "Meeting") is scheduled for 9:00 a.m. PST on Thursday, July 16, 2020. - The sole purpose of the Meeting is to seek approval of a proposal to amend Titan's certificate of incorporation to increase the number of authorized shares of common stock. - The amendment requires the favorable vote of 47,830,178 shares, a majority of the shares outstanding on the record date of May 22, 2020. - More affirmative votes are needed

• Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnership

  6/24/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Indegene Inc. to establish multichannel digital marketing programs throughout the United States and expand the capabilities for the engagement of health care providers ("HCPs") who are eli

• Titan Pharmaceuticals Launches Virtual REMS Training For Probuphine Health Care Providers

  6/16/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has initiated a fully-virtual Probuphine ®  (buprenorphine) implant Risk Evaluation and Mitigation Strategy ("REMS") training and certification program for qualified health care providers ("HCPs") who treat patients with Opioid U

• Titan Pharmaceuticals Reports First Quarter 2020 Financial Results

  5/15/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended March 31, 2020 and provided an update on its business.

• Titan Pharmaceuticals To Report First Quarter 2020 Financial Results On May 15, 2020

  5/11/2020

  Titan Pharmaceuticals, Inc. announced that its first quarter 2020 financial results will be released on Friday, May 15, 2020.

• Titan Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results

  3/30/2020

  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on its business.

• Titan Pharmaceuticals To Report Fourth Quarter And Full Year 2019 Financial Results On March 30, 2020

  3/26/2020

  Management Team to Host Conference Call on March 30, 2020 at 4:30 p.m. ET / 1:30 p.m. PT

• Titan Pharmaceuticals Receives $5.9 Million From Exercise Of Warrants

  3/5/2020

  Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that, since January 1, 2020 , it has received proceeds of approximately $5.9 million as a result of the exercise of approximately 26.2 million previously issued Class B common share purchase warrants (the "Class B Warrants").

• Titan Pharmaceuticals Announces Addition Of Probuphine® To Federal Supply Schedule

  1/13/2020

  Titan Pharmaceuticals, Inc. announced that it has signed an agreement for Probuphine implant to be included on the Federal Supply Schedule, providing U.S. veterans and other federal government agencies with access to Titan's novel 6-month maintenance treatment for Opioid Use Disorder in eligible patients.

• Titan Pharmaceuticals Announces Pricing of $2.2 Million Registered Direct Offering

  1/7/2020

  The combined purchase price for one share of common stock and each warrant will be $0.25.

• Titan Pharmaceuticals Appoints Dr. Kate DeVarney To Its Board Of Directors

  12/30/2019

  Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January 2007 and spearheaded the development of Probuphine® implant, the first six-month long acting product approved in the United States, Canada and Europe for the treatment of opioid use disorder in eligible patients.